Back to Search
DAVID LEBWOHL, MD
MD
Nephrology Physician
NPI: 1558377051Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
40140(MA)
Nephrology PhysicianPrimary
Internal Medicine — Nephrology
Code: 207RN0300X
40140(MA)
Research & Publications (20)
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
PMID 18446338·Cancer Chemother Pharmacol·2009
3-trial
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
PMID 18653228·Lancet·2008
3-trial
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
PMID 18332469·J Clin Oncol·2008
3-trial
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
PMID 18182676·J Clin Oncol·2008
8-other
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
PMID 17606973·J Clin Oncol·2007
3-trial
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
PMID 17606975·J Clin Oncol·2007
3-trial
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
PMID 17606972·J Clin Oncol·2007
3-trial
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
PMID 16730273·Semin Oncol·2006
6-review
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
PMID 16586011·Invest New Drugs·2006
3-trial
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
PMID 16172907·Cancer Chemother Pharmacol·2006
3-trial
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
PMID 15939265·Eur J Cancer·2005
3-trial
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
PMID 15741753·Oncology·2005
3-trial
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
PMID 15705616·Ann Oncol·2005
4-observational
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
PMID 15528984·Invest New Drugs·2005
3-trial
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
PMID 15345597·Blood·2005
3-trial
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
PMID 15124689·Ann Hematol·2004
3-trial
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
PMID 14977827·Clin Cancer Res·2004
3-trial
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
PMID 14722035·J Clin Oncol·2004
3-trial
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
PMID 12721265·J Clin Oncol·2003
3-trial
Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies.
PMID 12008664·Invest New Drugs·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 77 HERRICK ST, SUITE101
BEVERLY, MA 01915 - Phone
- (978) 927-4110
Quick Facts
- NPI
- 1558377051
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile